Kenyan Plasmodium falciparum field isolates: Correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 164-169

  Nzila Mounda, A ^a,b,c   Mberu, E K ^a,d   Sibley, C H ^c   Plowe, C V ^e   Winstanley, P A ^f   Watkins, W M ^a,b,f  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF NAIROBI   (Kenya)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORCYCLOGUANIL; DAPSONE; DIHYDROFOLATE REDUCTASE; FANSIDAR; PYRIMETHAMINE; SULFADOXINE;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIVITY; GENOTYPE; KENYA; MALARIA; NONHUMAN; PHARMACOGENETICS; PLASMODIUM FALCIPARUM; POINT MUTATION; PRIORITY JOURNAL;

EID: 0031963057     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.164     Document Type: Article

References (55)

1. Amukoye, E., P. A. Winstanley, W. M. Watkins, R. W. Snow, J. Hatcher, M. Mosobo, E. Ngumbao, B. Lowe, M. Ton, G. Minyiri, and K. Marsh. 1997. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 41:2261-2264.
2. Anabwani, G. M., F. O. Esamai, and D. A. Menya. 1996. A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar® in the treatment of uncomplicated malaria in children. East Afr. Med. J. 73:155-158.
3. Basco, L. K., P. Eldin de Pecoulas, C. M. Wilson, J. Le Bras, and A. Mazabraud. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 69:135-138.
4. Basco, L. K., P. Eldin de Pecoulas, J. Le Bras, and C. M. Wilson. 1996. Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates. Exp. Parasitol. 82:97-103.
5. Bloland, P. B., E. M. Lackritz, P. N. Kazembe, J. B. Were, R. Steketee, and C. C. Campbell. 1993. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J. Infect. Dis. 167:932-937.
6. Brandling Bennett, A. D., A. J. Oloo, W. M. Watkins, D. A. Boriga, D. M. Kariuki, and W. E. Collins. 1988. Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance. Trans. R. Soc. Trop. Med. Hyg. 82:833-837.
7. Brooks, D. R., P. Wang, M. Read, W. M. Watkins, P. F. Sims, and J. E. Hyde. 1994. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224:397-405.
8. Cha, R. S., H. Zarlb, P. Keohavong, and W. G. Thilly. 1992. Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. PCR Methods Applications 2:14-20.
9. Chulay, J. D., W. M. Watkins, and D. G. Sixsmith. 1984. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 33:325-330.
10. Cowman, A. F., M. J. Morry, B. A. Biggs, G. A. Cross, and S. J. Foote. 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 85:9109-9113.
11. Dieckmann, A., and A. Jung. 1986. Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 19:143-147.
12. Eldin de Pecoulas, P., L. K. Basco, B. Abdallah, M. K. Dje, J. Le Bras, and A. Mazabraud. 1995. Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp. Parasitol. 80: 483-487.
13. Ferone, R. 1977. Folate metabolism in malaria. Bull. W. H. O. 55:291-298.
14. Foote, S. J., D. Galatis, and A. F. Cowman. 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA 87:3014-3017.
15. Gyang, F. N., D. S. Peterson, and T. E. Wellems. 1992. Plasmodium falciparum: rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine. Exp. Parasitol. 74:470-472.
16. Haynes, J. D., C. L. Diggs, F. A. Hines, and R. E. Desjardins. 1976. Culture of human malaria parasite Plasmodium falciparum. Nature 263:767-769.
17. Huang, M. M., N. Arhneim, and M. F. Goodman. 1992. Extension of base mispairs by Taq polymerase: implication for single nucleotide discrimination in PCR. Nucleic Acids Res. 20:4567-4573.
18. Mberu, E. K., and W. M. Watkins. Unpublished data.
19. Milhous, W. K., N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1985. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob. Agents Chemother. 27:525-530.
20. Mwenesi, H., T. Harpham, K. Marsh, and R. W. Snow. 1995. Child malaria treatment among mothers in Kenya. Soc. Sci. Med. 49:1271-1277.
21. Newton, C. R., L. E. Heptinstall, C. Summers, M. Super, M. Schwarz, R. Anwar, A. Graham, J. C. Smith, and A. F. Markham. 1989. Amplification refractory mutation system for prenatal diagnosis and carrier assessment in cystic fibrosis. Lancet ii:1481-1483.
22. Pasvol, G., C. R. Newton, P. A. Winstanley, W. M. Watkins, N. M. Peshu, J. B. Were, K. Marsh, and D. A. Warrell. 1991. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am. J. Trop. Med. Hyg. 45:702-713.
23. Payne, D. 1987. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol. Today 3:241-246.
24. Peterson, D. S., D. Walliker, and T. E. Wellems. 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA 85: 9114-9118.
25. Peterson, D. S., W. K. Milhous, and T. E. Wellems. 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA 87:3018-3022.
26. Peterson, D. S., S. M. Di Santi, M. Povoa, V. S. Calvosa, V. E. do Rosario, and T. E. Wellems. 1991. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am. J. Trop. Med. Hyg. 45:492-497.
27. Plowe, C. V., A. Djimde, M. Bouare, O. Doumbo, and T. E. Wellems. 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 52:565-568.
28. Plowe, C. V., A. Djimde, T. E. Wellems, B. Kouriba, and O. K. Doumbo. 1996. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am. J. Trop. Med. Hyg. 55:467-471.
29. Plowe, C. V., J. F. Cortese, A. Djimde, O. C. Nwanyanwu, W. M. Watkins, P. A. Winstanley, J. G. Estrada-Franco, R. E. Mollinedo, J. C. Avila, J. L. Cespedes, D. Carter, and O. K. Doumbo. 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 176:1590-1596.
30. Poe, M. 1976. Antibacterial synergism: a proposal for chemotherapeutic potentiation between trimethoprim and sulfamethoxazole. Science 194:533-535.
31. Reeder, J. C., K. H. Rieckmann, B. L. Genton, K. Lorry, B. Wines, and A. F. Cowman. 1996. Point mutation in the dihydrofolate reductase and dihydropteroate synthase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg. 55:209-213.
32. Sarkar, G., J. Cassady, C. D. Bottema, and S. S. Sommer. 1990. Characterization of polymerase chain reaction amplification of specific alleles. Anal. Biochem. 186:64-68.
33. Sirawaraporn, W., and Y. Yuthavong. 1986. Potentiating effect of pyrimethamine and sulfadoxine against dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant Plasmodium chabaudi. Antimicrob. Agents Chemother. 29:899-905.
34. Sirawaraporn, W., T. Sathitkul, R. Sirawaraporn, Y. Yuthavong, and D. V. Santi. 1997. Antifolates-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. USA 94:1124-1129.
35. Sommer, S. S., A. R. Groszbach, and C. D. Bottema. 1992. PCR amplification of specific alleles (PASA) is a general method for rapidly detecting known single-base changes. BioTechniques 12:82-87.
36. Spencer, H. C., W. M. Watkins, D. G. Sixsmith, D. K. Koech, and J. D. Chulay. 1984. A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya. Bull. W. H. O. 62:615-621.
37. Spencer, H. C., W. M. Watkins, D. G. Sixsmith, and D. K. Koech. 1986. Response of Plasmodium falciparum to dihydrofolate reductase inhibitors in Malindi, Kenya. Trans. R. Soc. Trop. Med. Hyg. 80:201-203.
38. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
39. Trigg, J. K., H. Mbwana, O. Chambo, E. Hills, W. M. Watkins, and C. F. Curtis. 1997. Resistance to pyrimathamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Trop. 63:185-189.
40. Triglia, T., and A. F. Cowman. 1994. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 91:7149-7153.
41. Wang, P., M. Read, P. F. G. Sims, and J. E. Hyde. 1997. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutation in dihydropteroate synthethasc and an additional factor associated with tolate utilization. Mol. Microbiol. 23:979-986.
42. Wang, P., C. S. Lee, R. Bayoumi, A. Djimde, O. Doumbo, G. Swedberg, L. D. Dao, H. Mshinda, M. Tanner, W. M. Watkins, P. F. G. Sims, and J. E. Hyde. 1997. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthase and dihydrofolate reductase alleles in a large number of field isolates of diverse origins. Mol. Biochem. Parasitol. 89:161-177.
43. Watkins, W. M., D. G. Sixsmith, J. D. Chulay, and H. C. Spencer. 1985. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol. Biochem. Parasitol. 14:55-61.
44. Watkins, W. M., R. E. Howells, A. D. Brandling Bennett, and D. K. Koech. 1987. In vitro susceptibility of Plasmodium falciparum isolates from Jilore, Kenya, to antimalarial drugs. Am. J. Trop. Med. Hyg. 37:445-451.
45. Watkins, W. M., J. D. Chulay, D. G. Sixsmith, H. C. Spencer, and R. E. Howells. 1987. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J. Pharm. Pharmacol. 39:261-265.
46. Watkins, W. M., and M. Mosobo. 1993. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans. R. Soc. Trop. Med. Hyg. 87:75-78.
47. Watkins, W. M., E. K. Mberu, P. A. Winstanley, and C. Plowe. 1997. The efficacy of antifolate antimalarial combination in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today 13:459-464.
48. Wernsdorfer, W., and D. Payne. 1991. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol. Ther. 50:95-121.
49. Wilairatana, D. E., P. Kyle, S. Looaresuwan, K. Chingwongprom, S. Amradee, N. J. White, and W. M. Watkins. 1996. Efficacy of combinations of dapsone with proguanil and dapsone with chlorproguanil for acute uncomplicated falciparum malaria in Thailand. Ann. Trop. Med. Parasitol. 91:125-132.
50. Winstanley, P. A., E. K. Mberu, I. S. F. Szwandt, A. M. Breckenridge, and W. M. Watkins. 1995. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob. Agents Chemother. 39:948-952.
51. Winstanley, P. A., W. M. Watkins, D. Muhia, I. S. F. Szwandt, E. Amukoye, and K. Marsh. 1997. Chlorcycloguanil-dapsone for uncomplicated falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans. R. Soc. Trop. Med. Hyg. 91:322-327.
52. Wooden, J. M., L. H. Hartwell, B. Vasquez, and C. H. Sibley. 1997. Analysis of antimalarial drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol. Biochem. Parasitol. 85:24-40.
53. Zindrou, S., L. D. Dao, P. T. Xuyen, N. P. Dung, N. D. Sy, O. Skold, and G. Swedberg. 1996. Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Am. J. Trop. Med. Hyg. 5:185-188.
54. Zindrou, S., N. P. Dung, N. D. Sy, O. Skold, and G. Swedberg. 1996. Plasmodium falciparum: mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient. Exp. Parasitol. 84:56-64.
55. Zolg, J. W., J. R. Plitt, G. X. Chen, and S. Palmer. 1989. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 36:253-262.